Princeton molecular biologist Bonnie Bassler, emeritus professors Larry Martin Bartels and Ingrid Daubechies, and ...

CytomX’s workforce cuts could leave the biotech with fewer than 75 employees as it focuses resources on its wholly owned ...

GORTEC, known as Head and Neck Radiation Oncology Group, today announced that the randomized Phase 3 NIVOPOSTOP GORTEC 2018-01 trial evaluating nivolumab, Bristol Myers Squibb's anti-PD-1 therapy, as ...

We recently compiled a list of the Early Retirement Portfolio: 10 Stocks to Live Off Dividends. In this article, we are going ...

Failed to fetch dynamically imported module: https://uk.finance.yahoo.com/assets/_app/immutable/nodes/96.Cy8eSqq3.js ...

WASHINGTON, Jan 7 (Bernama-AA) -- US Senator Bernie Sanders pledged Monday to do everything he can to block arms sales to Israel, Anadolu Agency reported.

The trial is also investigating the therapy in combination with Opdivo (nivolumab) and chemotherapy as part of a collaboration agreement with Bristol Myers Squibb. This cohort has now been fully ...

Bristol Myers Squibb (NYSE:BMY) said it expects to report a Q4 net expense of $18M related to acquired IPRD and licensing ...

Cancer-focused CytomX Therapeutics Inc. will lay off 40% of its workforce — about 50 employees — to help extend its cash into ...

These seven blue-chip dividend stocks provide investors a steady stream of passive income and offer promising total return.

A protein kinase inhibitor is a type of enzyme inhibitor that can block the action of protein kinases. Protein kinase inhibitors can be subdivided according to the amino acid on a protein that they ...

Shares of Exelixis, Inc. EXEL have surged 50% in a year against the industry’s decline of 16.1%. The stock has also ...